Report Company Directory

Kinepolis Group NV

• Benelux Morning Notes by ING Financial Markets
• Morning Notes : AKZA NA, KIN BB, UCB BB, XIOR BB by KBC Securities
• Kinepolis/Moment of truth in 2026, M&A case gets real/BUY by ING Financial Markets
• Openbaarmaking van een transparantiekennisgeving by GlobeNewsWire
• Publication relative à une notification de transparence by GlobeNewsWire
• Publication of a transparency notification by GlobeNewsWire
• Morning Notes : AGS BB, AGFB BB, CPINV BB, DIE BB, IBAB BB, KIN BB, DEME BB by KBC Securities
• Benelux Morning Notes by ING Financial Markets
• Morning Notes : KIN BB, ONWD BB by KBC Securities
• Kinepolis Group One Battle After Another by KBC Securities

KINETA INC

• Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) by GlobeNewsWire
• Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors by GlobeNewsWire
• Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 by GlobeNewsWire
• Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 by GlobeNewsWire
• Kineta, Inc Transitioning from Nasdaq to OTC Markets by GlobeNewsWire
• Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer by GlobeNewsWire
• Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences by GlobeNewsWire
• Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities by GlobeNewsWire
• Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial by GlobeNewsWire
• Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update by GlobeNewsWire

KINETANA INTERNATIONAL BIOTECH PHARMA LTD.

Kinetic Concepts Inc.

Kinetic Engineering Ltd.

• Ford Equity International Rating and Forecast Report by Ford Equity Research